Data Insights

LUCARG-39D by Legend Biotech for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval

LUCARG-39D is under clinical development by Legend Biotech and currently in Phase I for B-Cell Non-Hodgkin Lymphoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - LUCARG-39D in B-Cell Non-Hodgkin Lymphoma

Data Insights

LUCARG-39D by Legend Biotech for Follicular Lymphoma: Likelihood of Approval

LUCARG-39D is under clinical development by Legend Biotech and currently in Phase I for Follicular Lymphoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - LUCARG-39D in Follicular Lymphoma

Data Insights

LUCARG-39D by Legend Biotech for Diffuse Large B-Cell Lymphoma: Likelihood of Approval

LUCARG-39D is under clinical development by Legend Biotech and currently in Phase I for Diffuse Large B-Cell Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - LUCARG-39D in Diffuse Large B-Cell Lymphoma

Data Insights

LB-1908 by Legend Biotech for Gastric Cancer: Likelihood of Approval

LB-1908 is under clinical development by Legend Biotech and currently in Phase I for Gastric Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - LB-1908 in Gastric Cancer

Data Insights

LB-1908 by Legend Biotech for Esophageal Cancer: Likelihood of Approval

LB-1908 is under clinical development by Legend Biotech and currently in Phase I for Esophageal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - LB-1908 in Esophageal Cancer

Data Insights

LB-1908 by Legend Biotech for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval

LB-1908 is under clinical development by Legend Biotech and currently in Phase I for Adenocarcinoma Of The Gastroesophageal Junction. According...

Likelihood of Approval and Phase Transition Success Rate Model - LB-1908 in Adenocarcinoma Of The Gastroesophageal Junction

Data Insights

LCAR-G08 by Legend Biotech for Pancreatic Cancer: Likelihood of Approval

LCAR-G08 is under clinical development by Legend Biotech and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - LCAR-G08 in Pancreatic Cancer

Data Insights

LB-1902 by Legend Biotech for Epithelial Ovarian Cancer: Likelihood of Approval

LB-1902 is under clinical development by Legend Biotech and currently in Phase I for Epithelial Ovarian Cancer. According to GlobalData,...

Data Insights

LB-1908 by Legend Biotech for Metastatic Adenocarcinoma of The Pancreas: Likelihood of Approval

LB-1908 is under clinical development by Legend Biotech and currently in Phase I for Metastatic Adenocarcinoma of The Pancreas. According...

Likelihood of Approval and Phase Transition Success Rate Model - LB-1908 in Metastatic Adenocarcinoma of The Pancreas

Data Insights

Risk adjusted net present value: What is the current valuation of Legend Biotech's LB-1908?

LB-1908 is a gene-modified cell therapy commercialized by Legend Biotech, with a leading Phase I program in Adenocarcinoma Of The...

Net Present Value Model: Legend Biotech Corp's LB-1908